In the case of CRC, two previous phase II trials of QDx5 single-agent TMZ in patients with pretreated, metastatic CRC reported an ORR of 12% and 10%, respectively, when utilizing prospective selection for MGMT deficiency [21, 22]. The gene discussed is MGMT; the disease is colorectal carcinoma.